OneTest for Cancer
Multi-Cancer Early Detection (MCED)
CommercialActive
Key Facts
About 20/20 BioLabs
20/20 BioLabs is a private, early-revenue diagnostics company pioneering AI-driven blood tests for early disease detection. Its core technology focuses on protein tumor markers and inflammatory biomarkers, offering a cost-effective and convenient at-home collection model. The company's lead commercial product is OneTest™ for Cancer, with a pipeline including OneTest for Longevity, positioning it in the competitive but high-growth markets of multi-cancer screening and proactive health management.
View full company profileTherapeutic Areas
Other Multi-Cancer Early Detection (MCED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Multi-Omics Early Detection Platform | PrognomiQ | Discovery/Pre-Clinical |
| miONCO | Xgenera | Pre-clinical |
| Early Cancer Detection | Burning Rock Biotech | R&D/Clinical Studies |